Detalhe da pesquisa
1.
Lasofoxifene as a potential treatment for aromatase inhibitor-resistant ER-positive breast cancer.
Breast Cancer Res
; 26(1): 95, 2024 Jun 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38849889
2.
Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer.
Breast Cancer Res
; 23(1): 54, 2021 05 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33980285
3.
Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome.
Nat Genet
; 32(1): 148-52, 2002 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-12172547
4.
Progesterone receptor isoforms, agonists and antagonists differentially reprogram estrogen signaling.
Oncotarget
; 9(4): 4282-4300, 2018 Jan 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29435103
5.
Identification of midkine as a mediator for intercellular transfer of drug resistance.
Oncogene
; 24(31): 4965-74, 2005 Jul 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-15897897
6.
Genomic agonism and phenotypic antagonism between estrogen and progesterone receptors in breast cancer.
Sci Adv
; 2(6): e1501924, 2016 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27386569
7.
Bcl-x(L) and Akt cooperate to promote leukemogenesis in vivo.
Oncogene
; 22(5): 688-98, 2003 Feb 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-12569361
8.
Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis.
Blood
; 101(11): 4298-300, 2003 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-12560215
9.
Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.
Blood Cells Mol Dis
; 31(3): 351-6, 2003.
Artigo
em Inglês
| MEDLINE | ID: mdl-14636651